Yi Wang, Yu Lei, Delai Zheng, Yanhui Yang, Lei Luo, Ji Li, Xiaoyang Xie
{"title":"接受免疫检查点抑制剂治疗的非小细胞肺癌患者肺部免疫预后指数的预后价值：一项荟萃分析。","authors":"Yi Wang, Yu Lei, Delai Zheng, Yanhui Yang, Lei Luo, Ji Li, Xiaoyang Xie","doi":"10.3389/pore.2024.1611773","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Until now, it has been difficult to accurately predict the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC). A novel indicator, the lung immune prognostic index (LIPI), has shown relatively high prognostic value in patients with solid cancer. Therefore, this study aimed to further identify the association between LIPI and the survival of patients with NSCLC who receive immune checkpoint inhibitors (ICIs).</p><p><strong>Methods: </strong>Several electronic databases were searched for available publications up to April 23, 2023. Immunotherapy outcomes included overall survival (OS), progression-free survival (PFS), and hazard ratios (HRs) with 95% confidence intervals (CIs). Subgroup analysis based on the study design and comparison of the LIPI was conducted.</p><p><strong>Results: </strong>In this meta-analysis, 21 studies with 9,010 patients were included in this meta-analysis. The pooled results demonstrated that elevated LIPI was significantly associated with poor OS (HR = 2.50, 95% CI:2.09-2.99, <i>p</i> < 0.001) and PFS (HR = 1.77, 95% CI:1.64-1.91, <i>p</i> < 0.001). Subgroup analyses stratified by study design (retrospective vs. prospective) and comparison of LIPI (1 vs. 0, 2 vs. 0, 1-2 vs. 0, 2 vs. 1 vs. 0, 2 vs. 0-1 and 2 vs. 1) showed similar results.</p><p><strong>Conclusion: </strong>LIPI could serve as a novel and reliable prognostic factor in NSCLC treated with ICIs, and elevated LIPI predicts worse prognosis.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611773"},"PeriodicalIF":2.3000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222319/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis.\",\"authors\":\"Yi Wang, Yu Lei, Delai Zheng, Yanhui Yang, Lei Luo, Ji Li, Xiaoyang Xie\",\"doi\":\"10.3389/pore.2024.1611773\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and purpose: </strong>Until now, it has been difficult to accurately predict the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC). A novel indicator, the lung immune prognostic index (LIPI), has shown relatively high prognostic value in patients with solid cancer. Therefore, this study aimed to further identify the association between LIPI and the survival of patients with NSCLC who receive immune checkpoint inhibitors (ICIs).</p><p><strong>Methods: </strong>Several electronic databases were searched for available publications up to April 23, 2023. Immunotherapy outcomes included overall survival (OS), progression-free survival (PFS), and hazard ratios (HRs) with 95% confidence intervals (CIs). Subgroup analysis based on the study design and comparison of the LIPI was conducted.</p><p><strong>Results: </strong>In this meta-analysis, 21 studies with 9,010 patients were included in this meta-analysis. The pooled results demonstrated that elevated LIPI was significantly associated with poor OS (HR = 2.50, 95% CI:2.09-2.99, <i>p</i> < 0.001) and PFS (HR = 1.77, 95% CI:1.64-1.91, <i>p</i> < 0.001). Subgroup analyses stratified by study design (retrospective vs. prospective) and comparison of LIPI (1 vs. 0, 2 vs. 0, 1-2 vs. 0, 2 vs. 1 vs. 0, 2 vs. 0-1 and 2 vs. 1) showed similar results.</p><p><strong>Conclusion: </strong>LIPI could serve as a novel and reliable prognostic factor in NSCLC treated with ICIs, and elevated LIPI predicts worse prognosis.</p>\",\"PeriodicalId\":19981,\"journal\":{\"name\":\"Pathology & Oncology Research\",\"volume\":\"30 \",\"pages\":\"1611773\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222319/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology & Oncology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/pore.2024.1611773\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology & Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/pore.2024.1611773","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的：迄今为止，非小细胞肺癌（NSCLC）患者的免疫疗法疗效一直难以准确预测。肺免疫预后指数（LIPI）这一新型指标在实体瘤患者中显示出相对较高的预后价值。因此，本研究旨在进一步确定LIPI与接受免疫检查点抑制剂（ICIs）治疗的NSCLC患者生存期之间的关系：方法：在多个电子数据库中检索了截至2023年4月23日的文献。免疫治疗结果包括总生存期（OS）、无进展生存期（PFS）、危险比（HRs）及95%置信区间（CIs）。根据研究设计和LIPI的比较进行了分组分析：本次荟萃分析共纳入21项研究，9010名患者。汇总结果显示，LIPI升高与OS（HR=2.50，95% CI:2.09-2.99，p＜0.001）和PFS（HR=1.77，95% CI:1.64-1.91，p＜0.001）差显著相关。根据研究设计（回顾性与前瞻性）和LIPI的比较（1 vs. 0、2 vs. 0、1-2 vs. 0、2 vs. 1 vs. 0、2 vs. 0-1和2 vs. 1）进行的亚组分析显示了相似的结果：结论：LIPI可作为接受ICIs治疗的NSCLC患者的一个新的、可靠的预后因素，LIPI升高预示着预后较差。
Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis.
Background and purpose: Until now, it has been difficult to accurately predict the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC). A novel indicator, the lung immune prognostic index (LIPI), has shown relatively high prognostic value in patients with solid cancer. Therefore, this study aimed to further identify the association between LIPI and the survival of patients with NSCLC who receive immune checkpoint inhibitors (ICIs).
Methods: Several electronic databases were searched for available publications up to April 23, 2023. Immunotherapy outcomes included overall survival (OS), progression-free survival (PFS), and hazard ratios (HRs) with 95% confidence intervals (CIs). Subgroup analysis based on the study design and comparison of the LIPI was conducted.
Results: In this meta-analysis, 21 studies with 9,010 patients were included in this meta-analysis. The pooled results demonstrated that elevated LIPI was significantly associated with poor OS (HR = 2.50, 95% CI:2.09-2.99, p < 0.001) and PFS (HR = 1.77, 95% CI:1.64-1.91, p < 0.001). Subgroup analyses stratified by study design (retrospective vs. prospective) and comparison of LIPI (1 vs. 0, 2 vs. 0, 1-2 vs. 0, 2 vs. 1 vs. 0, 2 vs. 0-1 and 2 vs. 1) showed similar results.
Conclusion: LIPI could serve as a novel and reliable prognostic factor in NSCLC treated with ICIs, and elevated LIPI predicts worse prognosis.
期刊介绍：
Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
